Kopra Bio

Kopra Bio is pioneering a novel approach to cancer treatment through genetically engineered viruses. Leveraging technology developed at UCSF, these viruses are designed to educate the patient's immune system to effectively target and eliminate cancerous cells. The company's primary objective is to create the next breakthrough cancer therapy, aiming for a similar impact as Keytruda, a $25 billion per year blockbuster drug. Kopra Bio is initially focusing on glioblastoma, one of the most aggressive forms of brain cancer. Preclinical results are promising, demonstrating a significant improvement in survival rates from 0% with current FDA-approved treatments to 90% with Kopra Bio's innovative therapy in challenging brain cancer models.